Literature DB >> 19266341

VelociMouse: fully ES cell-derived F0-generation mice obtained from the injection of ES cells into eight-cell-stage embryos.

Thomas M Dechiara1, William T Poueymirou, Wojtek Auerbach, David Frendewey, George D Yancopoulos, David M Valenzuela.   

Abstract

With the completion of the human and mouse genome sequences and the development of high-throughput knockout mouse technologies, there is now a need for equally high-throughput methods for the production of mice for phenotypic studies. In response to this challenge, we recently developed a new method termed VelociMouse for the production of F0-generation mice that are fully derived from gene-targeted ES cells. In the version of the VelociMouse method described here, laser ablation of a portion of the zona pellucid (zp) of a normal eight-cell-stage embryo facilitates ES cell injection. Upon gestation in a surrogate mother, the injected embryos produce F0 mice that carry no detectable host embryo contribution (<0.1%). The fully ES cell-derived mice are normal, healthy, and fertile and exhibit 100% germline transmission for optimal breeding efficiency. The VelociMouse method accommodates both inbred or hybrid ES cells and either inbred or outbred eight-cell host embryos. Because the F0 mice produced are suitable for direct phenotyping studies, the VelociMouse method, coupled with high-throughput ES cell targeting technologies, such as VelociGene, offers an accelerated path to new drug target discovery and validation and a revolutionary approach to realize the full value of large-scale functional genomic efforts, such as the NIH Knockout Mouse Project ( 1 ) and the European Conditional Mouse Mutagenesis Project( 9 ).

Entities:  

Mesh:

Year:  2009        PMID: 19266341     DOI: 10.1007/978-1-59745-471-1_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  Mouse models of X-linked juvenile retinoschisis have an early onset phenotype, the severity of which varies with genotype.

Authors:  Yang Liu; Junzo Kinoshita; Elena Ivanova; Duo Sun; Hong Li; Tara Liao; Jingtai Cao; Brent A Bell; Jacob M Wang; Yajun Tang; Susannah Brydges; Neal S Peachey; Botir T Sagdullaev; Carmelo Romano
Journal:  Hum Mol Genet       Date:  2019-09-15       Impact factor: 6.150

2.  Cloning mice and men: prohibiting the use of iPS cells for human reproductive cloning.

Authors:  Bernard Lo; Lindsay Parham; Arturo Alvarez-Buylla; Marcelle Cedars; Bruce Conklin; Susan Fisher; Elena Gates; Linda Giudice; Dina Gould Halme; William Hershon; Arnold Kriegstein; Pui-Yan Kwok; Richard Wagner
Journal:  Cell Stem Cell       Date:  2010-01-08       Impact factor: 24.633

3.  Diverse Phenotypes and Specific Transcription Patterns in Twenty Mouse Lines with Ablated LincRNAs.

Authors:  Ka-Man Venus Lai; Guochun Gong; Amanda Atanasio; José Rojas; Joseph Quispe; Julita Posca; Derek White; Mei Huang; Daria Fedorova; Craig Grant; Lawrence Miloscio; Gustavo Droguett; William T Poueymirou; Wojtek Auerbach; George D Yancopoulos; David Frendewey; John Rinn; David M Valenzuela
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

4.  ANGPTL7, a therapeutic target for increased intraocular pressure and glaucoma.

Authors:  Kavita Praveen; Gaurang C Patel; Lauren Gurski; Ariane H Ayer; Trikaladarshi Persaud; Matthew D Still; Lawrence Miloscio; Tavé Van Zyl; Silvio Alessandro Di Gioia; Ben Brumpton; Kristi Krebs; Bjørn Olav Åsvold; Esteban Chen; Venkata R M Chavali; Wen Fury; Harini V Gudiseva; Sarah Hyde; Eric Jorgenson; Stephanie Lefebvre; Dadong Li; Alexander Li; James Mclninch; Brijeshkumar Patel; Jeremy S Rabinowitz; Rebecca Salowe; Claudia Schurmann; Anne-Sofie Seidelin; Eli Stahl; Dylan Sun; Tanya M Teslovich; Anne Tybjærg-Hansen; Cristen Willer; Scott Waldron; Sabrina Walley; Hua Yang; Sarthak Zaveri; Ying Hu; Kristian Hveem; Olle Melander; Lili Milani; Stefan Stender; Joan M O'Brien; Marcus B Jones; Gonçalo R Abecasis; Michael N Cantor; Jonathan Weyne; Katia Karalis; Aris Economides; Giusy Della Gatta; Manuel A Ferreira; George D Yancopoulos; Aris Baras; Carmelo Romano; Giovanni Coppola
Journal:  Commun Biol       Date:  2022-10-03

5.  Multi-Tissue Acceleration of the Mitochondrial Phosphoenolpyruvate Cycle Improves Whole-Body Metabolic Health.

Authors:  Abudukadier Abulizi; Rebecca L Cardone; Romana Stark; Sophie L Lewandowski; Xiaojian Zhao; Joelle Hillion; Lingjun Ma; Raghav Sehgal; Tiago C Alves; Craig Thomas; Charles Kung; Bei Wang; Stephan Siebel; Zane B Andrews; Graeme F Mason; Jesse Rinehart; Matthew J Merrins; Richard G Kibbey
Journal:  Cell Metab       Date:  2020-11-03       Impact factor: 27.287

6.  Rapidly generating knockout mice from H19-Igf2 engineered androgenetic haploid embryonic stem cells.

Authors:  Meili Zhang; Yufang Liu; Guang Liu; Xin Li; Yuyan Jia; Lihong Sun; Liu Wang; Qi Zhou; Yue Huang
Journal:  Cell Discov       Date:  2015-11-03       Impact factor: 10.849

7.  C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice.

Authors:  Amanda Atanasio; Vilma Decman; Derek White; Meg Ramos; Burcin Ikiz; Hoi-Ching Lee; Chia-Jen Siao; Susannah Brydges; Elizabeth LaRosa; Yu Bai; Wen Fury; Patricia Burfeind; Ralica Zamfirova; Gregg Warshaw; Jamie Orengo; Adelekan Oyejide; Michael Fralish; Wojtek Auerbach; William Poueymirou; Jan Freudenberg; Guochun Gong; Brian Zambrowicz; David Valenzuela; George Yancopoulos; Andrew Murphy; Gavin Thurston; Ka-Man Venus Lai
Journal:  Sci Rep       Date:  2016-03-16       Impact factor: 4.379

Review 8.  Engineering Antibodies for the Treatment of Infectious Diseases.

Authors:  Gaowei Fan; Jinming Li
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.